“Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”, J of Skin, vol. 1, no. 3.1, p. s26, Oct. 2017, doi: 10.25251/skin.1.supp.25.